Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

A Randomized, Single Blind, Placebo-controlled, Multiple Dose, Parallel-arm Study to Investigate the Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat to Treat COVID-19 (NICCAM)

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04750759

Acronym

NICCAM

Enrollment

Registered

2021-02-11

Start date

2021-02-03

Completion date

2021-10-29

Last updated

2021-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

Niclosamide (2000 mg QD) and Camostate (600 mg QID) are expected to be safe and well-tolerated as a combination therapy and to show clinically beneficial for COVID-19 patients.

Detailed description

Niclosamide is an approved drug for the treatment of intestinal worm infections that can potentially induce the process of autophagy and thus significantly limit viral replication in cells. Camostat is approved in Japan for the treatment of chronic pancreatitis and reflux esophagitis. It has been shown to effectively block viral replication in a SARS-CoV-2 animal model. Since the mechanisms of actions are different, it was hypothesized that a combination of both substances might have an additive or even synergistic effect in the treatment of patients with COVID-19. This study is designed to investigate the safety, tolerability and preliminary efficacy of the treatment combination niclosamide and camostat in mild and moderately affected COVID-19 patients.

Interventions

DRUGNiclosamide + Camostat

Niclosamide will be applied in combination with camostat.

OTHERPlacebo

Placebo to interventional drug

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Male and female patients in the age of 18 to 70 years * Having a recent positive direct test for Sars-CoV-2 * Having mild or moderate COVID-19 symptoms with no indication for hospitalization due to SARS-CoV-2 infection (WHO Ordinal Scale 1-2)

Exclusion criteria

* Severe respiratory symptoms related to COVID-19 requiring oxygen or intensive care (high flow oxygen or mechanical ventilation or ECMO) * Patients with preexisting pulmonary diseases requiring oxygen supply * Patients with history of hypersensitivity to Camostat or Niclosamide or to any ingredients to any of the two drugs * Patients with heart failure (NYHA III or NYHA IV) * Patients with proven malignant tumor * Patients diagnosed with influenza infection * Pregnancy or breastfeeding * Immunocompromised patients * Creatinine clearance \< 60 mL/min * aspartate aminotransferase (AST) / alanine aminotransferase (ALT) \> 2 times upper limit of normal (ULN)

Design outcomes

Primary

Measure	Time frame	Description
Treatment emergent number of Adverse Events	21 days	All pathological and clinically significant findings in physical examinations, vital signs, 12-lead ECGs, oxygen saturation and safety lab including coagulation will be documented as adverse events. Adverse events will be reported on the basis of CTCAE v5.0.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026